资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein

Nat Commun.. 2019;

Tang A1, Chen Z1, Cox KS1, Su HP2, Callahan C1, Fridman A3, Zhang L1, Patel SB2, Cejas PJ1, Swoyer R1, Touch S1, Citron MP1, Govindarajan D1,4, Luo B5, Eddins M2, Reid JC2, Soisson SM2, Galli J1, Wang D1, Wen Z1, Heidecker GJ1, Casimiro DR1,6, DiStefano DJ1, Vora KA7.

Products/Services Used	Details	Operation
Recombinant Proteins	Cell culture supernatant was collected, centrifuged and filtered. Filtered supernatant was loaded onto a Protein A CIP column (GenScript).	Get A Quote

摘要

Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant mortality under six months of age worldwide; therefore, the prevention of RSV infection in all infants represents a significant unmet medical need. Here we report the isolation of a potent and broadly neutralizing RSV monoclonal antibody derived from a human memory B-cell. This antibody, RB1, is equipotent on RSV A and B subtypes, potently neutralizes a diverse panel of clinical isolates in vitro and demonstrates in vivo protection. It binds to a highly conserved epitope in antigenic site IV of the RSV fusion glycoprotein. RB1 is the parental antibody to MK-1654 which is currently in clinical development for the preve... More